Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $15.
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $15.